Type 2 diabetes patient with muscle aches on statin therapy

2010 ◽  
Vol 3 (1) ◽  
Author(s):  
Patrick Twomey
Keyword(s):  
Type 2 Diabetes ◽  
Statin Therapy ◽  
Diabetes Patient

scholarly journals Improving Type 2 Diabetes Patient Health Outcomes with Individualized Continuing Medical Education for Primary Care

2016 ◽  
Vol 7 (3) ◽  
pp. 473-481 ◽  
Author(s):  
Brian Lee ◽  
Dace Trence ◽  
Silvio Inzucchi ◽  
Jay Lin ◽  
Steven Haimowitz ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Primary Care ◽  
Medical Education ◽  
Health Outcomes ◽  
Continuing Medical Education ◽  
Diabetes Patient ◽  
Patient Health

scholarly journals Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial

2018 ◽  
Vol 20 (6) ◽  
pp. 1479-1489 ◽  
Author(s):  
Kausik K. Ray ◽  
Lawrence A. Leiter ◽  
Dirk Müller-Wieland ◽  
Bertrand Cariou ◽  
Helen M. Colhoun ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Trial ◽  
Statin Therapy ◽  
Lipid Lowering

scholarly journals Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

2020 ◽  
Vol 105 (12) ◽  
pp. e4593-e4604 ◽  
Author(s):  
Ildiko Lingvay ◽  
Matthew S Capehorn ◽  
Andrei-Mircea Catarig ◽  
Pierre Johansen ◽  
Jack Lawson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Meta Analysis ◽  
Indirect Comparison ◽  
Diabetes Patient ◽  
Metformin Monotherapy ◽  
Efficacy Measures ◽  
Meta Regression ◽  
Glucagon Like Peptide 1

Abstract Context No head-to-head trials have directly compared once-weekly (OW) semaglutide, a human glucagon-like peptide-1 analog, with empagliflozin, a sodium–glucose co-transporter-2 inhibitor, in type 2 diabetes (T2D). Objective We indirectly compared the efficacy of OW semaglutide 1 mg vs once-daily (OD) empagliflozin 25 mg in patients with T2D inadequately controlled on metformin monotherapy, using individual patient data (IPD) and meta-regression methodology. Design, Setting, Participants, and Interventions IPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) were included. Meta-regression analyses were adjusted for potential prognostic factors and effect modifiers. Main Outcome Measures The primary efficacy outcomes were change from baseline to end-of-treatment (~1 year) in HbA1c (%-point) and body weight (kg). Responder outcomes and other clinically relevant efficacy measures were analyzed. Results Baseline characteristics were similar between OW semaglutide (n = 995) and empagliflozin (n = 410). Our analyses showed that OW semaglutide significantly reduced mean HbA1c and body weight vs empagliflozin (estimated treatment difference: −0.61%-point [95% confidence interval (CI): −0.72; −0.49] and −1.65 kg [95% CI: −2.22; −1.08], respectively; both P < 0.0001). Complementary analyses supported the robustness of these results. A significantly greater proportion of patients on OW semaglutide vs empagliflozin also achieved HbA1c targets and weight-loss responses. Conclusions This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy.

Sign in / Sign up

Export Citation Format

Share Document